Venous thromboembolism studies of apixaban and its clinical use

Abstract

Traditional treatment of venous tromboembolism requieres initiation of anticoagulation with heparin and low molecular weight heparin which is followed by warfarin use between 3-6 months. Warfarin has a narrow therapeutic range and a wide range of food interactions. To overcome the difficulties of the treatment with warfarin, new oral anticoagulant agents (NOACs) had been discovered after long years of research processes. In this review, the use of these agents, especially of apixaban, will be discussed in the treatment of venous thromboembolism.